SANGAMO THERAPEUTICS INC's ticker is SGMO and the CUSIP is 800677106. A total of 172 filers reported holding SANGAMO THERAPEUTICS INC in Q4 2017. The put-call ratio across all filers is 0.73 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $23,319 | -41.7% | 13,249 | +4.0% | 0.00% | -60.0% |
| Q4 2022 | $39,985 | +471.2% | 12,734 | +848.9% | 0.01% | +400.0% |
| Q3 2022 | $7,000 | -56.2% | 1,342 | -65.5% | 0.00% | -50.0% |
| Q2 2022 | $16,000 | +1500.0% | 3,892 | +2287.7% | 0.00% | – |
| Q1 2022 | $1,000 | – | 163 | +83.1% | 0.00% | – |
| Q1 2020 | $0 | – | 89 | +50.8% | 0.00% | – |
| Q4 2019 | $0 | – | 59 | 0.0% | 0.00% | – |
| Q3 2019 | $0 | – | 59 | 0.0% | 0.00% | – |
| Q2 2019 | $0 | – | 59 | 0.0% | 0.00% | – |
| Q1 2019 | $0 | – | 59 | 0.0% | 0.00% | – |
| Q4 2018 | $0 | -100.0% | 59 | 0.0% | 0.00% | – |
| Q3 2018 | $1,000 | – | 59 | 0.0% | 0.00% | – |
| Q2 2018 | $0 | -100.0% | 59 | -88.5% | 0.00% | -100.0% |
| Q1 2018 | $9,000 | +12.5% | 514 | 0.0% | 0.00% | 0.0% |
| Q4 2017 | $8,000 | +14.3% | 514 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $7,000 | +75.0% | 514 | 0.0% | 0.00% | +50.0% |
| Q2 2017 | $4,000 | +100.0% | 514 | 0.0% | 0.00% | +100.0% |
| Q1 2017 | $2,000 | – | 514 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Alexandria Capital, LLC | 1,003,725 | $15,663,000 | 1.66% |
| Golden State Equity Partners | 123,817 | $1,932,000 | 1.33% |
| Rhenman & Partners Asset Management AB | 821,888 | $12,826,000 | 1.05% |
| WASATCH ADVISORS LP | 10,072,381 | $157,180,000 | 0.77% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 29,636 | $462,000 | 0.73% |
| Ceeto Capital Group, LLC | 80,000 | $1,248,000 | 0.63% |
| EMC Capital Management | 48,992 | $765,000 | 0.58% |
| Fort Sheridan Advisors LLC | 71,173 | $1,111,000 | 0.54% |
| Vanguard Capital Wealth Advisors | 34,680 | $584,000 | 0.54% |
| Casdin Capital, LLC | 1,080,000 | $16,853,000 | 0.50% |